{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:10:47Z","timestamp":1762524647378,"version":"build-2065373602"},"reference-count":0,"publisher":"African Journals Online (AJOL)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Afr H. Sci."],"abstract":"<jats:p>Background: The purpose of the present study was to explore the effect of phosphodiesterase 4 (PDE-4) inhibitor combined with secukinumab monoclonal antibody on the activation level of p38 mitogen-activated protein kinases (p38MAPK) in psoriatic leukocytes.Methodology: The clinical data of 60 patients with psoriasis were retrospectively analyzed, and they were divided into a control group (secukinumab monotherapy, 30 cases) and a study group (PDE-4 inhibitory therapy). Agent combined with secukinumab treatment(30 cases), all were treated for 3 months. The Psoriasis Area and Severity Index (PASI), clinical symptom score, serum inflammatory factors, p38MAPK gene expression in lesion tissue, and clinical outcome were compared between the two groups.Results: After treatment, the PSAI score (t=5.051) and symptom score (t=14.102) of the study group were lower than those of the control group, and the relative expression of interleukin-6 (IL-6) (t=7.514) and p38MAPK (t=4.219), the relative expression of interleukin-17 (IL-17) (t=2.579) was lower than that of the control group. The total effective rate in the study group (83.33% vs. 60.00%) was higher than that in the control group.Conclusion: Secukinumab along with phosphodiesterase 4 inhibitors reduces p38MAPK activation, and improves immune response, inflammation, and clinical symptoms in patients with psoriasis.\r\nKeywords: Psoriasis; phosphodiesterase 4 inhibitor; secukinumab secukinumab; p38 MAPK.<\/jats:p>","DOI":"10.4314\/ahs.v25i1.35","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:43:38Z","timestamp":1753875818000},"source":"Crossref","is-referenced-by-count":0,"title":["Phosphodiesterase 4 inhibitor combined with secukinumab relieves clinical symptoms in patients with psoriasis via regulating p38MAPK activation and the immune response inflammation"],"prefix":"10.4314","volume":"25","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huani","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changzheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2895","published-online":{"date-parts":[[2025,5,9]]},"container-title":["African Health Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/295222\/277801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/295222\/277801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:06:26Z","timestamp":1762524386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/view\/295222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,9]]}},"URL":"https:\/\/doi.org\/10.4314\/ahs.v25i1.35","relation":{},"ISSN":["1729-0503","1680-6905"],"issn-type":[{"type":"electronic","value":"1729-0503"},{"type":"print","value":"1680-6905"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}